
Sage Therapeutics appoints Dr Jeffrey Jonas as chief executive
pharmafile | August 19, 2013 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Dr Jonas, Sage, ShireÂ
Sage Therapeutics has poached Shire’s Dr Jeffrey Jonas as the biotech industry veteran becomes the new chief executive of the company.
Before joining Shire, Jonas was executive VP of Isis Pharmaceuticals and chief medical officer of Forest Laboratories.
His latest role was as president of regenerative medicines at Irish rare drugs specialist Shire.
The firm has made several other key appointments, which include AstraZeneca’s Stephen Kanes as its new chief medical officer, and Santhera’s Kimi Iguchi as its chief financial officer.
Related Content

Takeda plans to vacate all 1,000 staff from US HQ by the year’s end
Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, …

Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion
Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss …

Top Ten most popular articles on Pharmafile.com this week!
With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger …






